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VIRO-TypeNed is a collaborative molecular surveil-
lance platform facilitated through a web-based 
database. Genetic data in combination with epidemio-
logical, clinical and patient data are shared between 
clinical and public health laboratories, as part of the 
surveillance underpinning poliovirus eradication. We 
analysed the combination of data submitted from 2010 
to 2014 to understand circulation patterns of non-polio 
enteroviruses (NPEV) of public health relevance. Two 
epidemiological patterns were observed based on 
VIRO-TypeNed data and classical surveillance data 
dating back to 1996: (i) endemic cyclic, characterised 
by predictable upsurges/outbreaks every two to four 
years, and (ii) epidemic, where rare virus types caused 
upsurges/outbreaks. Genetic analysis suggests con-
tinuous temporal displacement of virus lineages 
due to the accumulation of (silent) genetic changes. 
Non-synonymous changes in the antigenic B/C loop 
suggest antigenic diversification, which may affect 
population susceptibility. Infections were frequently 
detected at an age under three months and at an older, 
parenting age (25–49 years) pointing to a distinct role 
of immunity in the circulation patterns. Upsurges were 
detected in the summer and winter which can promote 
increased transmissibility underlying new (cyclic) 
upsurges and requires close monitoring. The combina-
tion of data provide a better understanding of NPEV 
circulation required to control and curtail upsurges 
and outbreaks.
Introduction
Enteroviruses (EVs) are widespread viruses circulat-
ing globally. More than 100 types, classified to the 
four species A to D within the genus Enterovirus of the 
Picornaviridae family, are known to infect and cause 
disease in humans [1] The epidemiology of enterovi-
ruses is characterised by the occurrence of seasonal 
peaks in the summer and temporal outbreaks that can 
be associated with life-threatening EV infections [2]. 
Clinical manifestations vary and range from asympto-
matic or mild respiratory or gastrointestinal symptoms 
to severe and even fatal cases of myocarditis, neona-
tal sepsis, and central nervous system infections [3,4]. 
Severe and fatal cases often occur in children younger 
than five years or immunocompromised individuals 
[5-11]. Unfortunately, treatment options are limited 
and specific antivirals are not yet available [12,13]. 
Enteroviruses evolve by genetic diversification and 
recombination [14-17], which may affect their virulence 
[18-30]. In the Asian Pacific Region, EV-A71 (genotype 
C4) has been causing large outbreaks of hand, foot and 
mouth disease (HFMD) with severe complications since 
2008 [22,23]. In a recent outbreak in the United States 
(US) and in Europe, an EV-D68 variant has been asso-
ciated with outbreaks of severe respiratory disease 
and possibly paralysis [24-30]. While vaccination is a 
proven control strategy for some picornaviruses (polio-
virus (PV), hepatitis A virus), little is known about the 
impact on population level of non-polio enteroviruses 
(NPEVs), even though these are among the most com-
mon endemic viruses. Knowledge on trends of NPEV 
illness comes from the decade-old EV surveillance pro-
grammes that have been implemented globally, where 
typing of enteroviruses from clinical samples from 
patients with polio-like illness is a cornerstone in the 
PV eradication campaign. Typing has historically been 
done by use of antigenic characterisation of virus iso-
lates from routine diagnostic laboratories that used 
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Figure 1
Distribution of endemic enterovirus types, the Netherlands, 1996–2014 (classical surveillance; n = 4,098) and 2010–2014 
(VIRO-TypeNed; n = 714)
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Lineages are indicated in boxes in the graphs. Black bars indicate classical surveillance. Orange bars indicate VIRO-TypeNed data.
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cell culture as the primary diagnostic method. Now 
laboratories are switching more and more to molecular 
detection and typing methods [31,32]. A major draw-
back of the widespread introduction of fast molecular 
diagnostic methods is that the surveillance spin-off of 
NPEV from the EV surveillance programme is no longer 
routinely available, and that molecular typing is dedi-
cated to a few larger diagnostic and university hospi-
tal centres. To compensate for this, we have launched 
a collaborative molecular surveillance programme in 
2010, in which sequence-based surveillance was intro-
duced (VIRO-TypeNed) [33]. 
Here, we present an analysis of data submitted through 
this novel surveillance system from 2010 through 2014, 
which provides a better understanding of NPEV circula-
tion in relation to seasonal epidemics and outbreaks.
Methods
Sampling and laboratory enterovirus diagnostic 
testing
Stool, respiratory, cerebrospinal fluid (CSF), blood and 
vesicle fluid samples from patients of different age 
groups, admitted to or visiting the hospital with an 
EV-associated illness, were sent to the clinical virology 
laboratories for testing. Symptoms varied from mild to 
severe respiratory illness, fever and appearance of ves-
icles to central nervous symptoms such as meningitis. 
Enterovirus testing were done by enterovirus-specific 
PCR tests [34,35], which are based on the conserved 
5’UTR and enable detection of both PV and NPEVs, 
including those that do not grow in cell culture [36,37].
Virus characterisation of 5’UTR-positive 
samples
Positive samples were characterised directly from clini-
cal material or culture-positive samples by sequencing 
the VP1 gene [31,38-40]. The VP1 partial sequences 
obtained were used as input in the typing tool with an 
automated algorithm to assign the species and (sub)
type of the sequences entered [41]. In addition, sam-
ples that could not be typed, in particular those with 
suspicion of PV infection, were sent to the reference 
laboratory (National Institute for Public Health and the 
Environment (RIVM)) for cultivation on the PV-specific 
cell line L20B to document the absence of wild-type 
PV circulation. Laboratories that do not perform typing 
of EVs are encouraged to send EV isolates or 5’UTR-
positive samples to the RIVM for exclusion of PV and 
further characterisation.
Reporting of data for EV surveillance by 
VIRO-TypeNed
The concept of VIRO-TypeNed has been described in 
detail elsewhere [33]. In short, participating Dutch 
clinical virology laboratories and the RIVM agreed on 
a consensus typing method described by Nix et al. 
[42] and on sharing of anonymised data in compli-
ance with privacy rules via a secured web-based data-
base. For each patient with a positive 5’UTR sample, 
at least one sequence of the VP1 gene generated by 
the Nix method is shared [40,42]. Sequences gener-
ated by other protocols can be included as well [43], 
but can only be included in the phylogenetic analysis 
when the region is compatible with the region gener-
ated with the Nix protocol. The VIRO-TypeNed platform 
includes a sequence-based typing tool with an auto-
mated algorithm to assign the species and (sub)type 
of the sequences entered, thus assuring comparabil-
ity between the laboratories [41]. When available, a 
minimum set of clinical and epidemiological data are 
included with the submitted sequences, consisting 
of age, sex, date and type of sample, hospitalisation, 
travel history, clinical symptoms (skin, neurological, 
respiratory, enteric and other) and mortality.
Data analysis
We analysed data submitted during the first five years 
of the VIRO-TypeNed project for trends, clusters and 
genetic diversity of common enteroviruses. Using data 
from the classical enterovirus surveillance containing 
data dating back to 1996 [32], the circulation patterns 
of the types were defined as endemic cyclic or as epi-
demic: (i) types with an endemic cyclic pattern of cir-
culation were characterised by (predictable) seasonal 
increases every two to four years, with low detection 
levels in intervening years and (ii) types with an epi-
demic pattern were characterised by a unique outbreak 
in a given year while being rare (detection level n < 10) 
for at least 10 years before the given year [32].
To identify potential viral factors underlying the cir-
culation patterns, all available partial VP1 gene 
sequences, which included the putative immunogenic 
B/C loop [44], were aligned and analysed for nucleo-
tide and amino acid changes between lineages using 
the Simmonics sequence editor [45]. Pairwise distribu-
tion based on the nucleotide sequences of VP1 was cal-
culated by MEGA6 [46] and used to set a demarcation 
cut-off to define lineages [47,48]. With the exception of 
EV-A71, classification of many NPEVs into lineages is 
not standardised. In cases where there is no uniform 
accepted lineage classification, lineages were desig-
nated alphabetically. EV-D68 lineages were designated 
as proposed by Tokarz et al. (A–C) [49] and Meijer et 
al. (I–III) [50].
Results
In the period from 2010 through 2014, six diagnostic and 
university hospital laboratories from different parts of 
the Netherlands participated in the network (University 
Medical Center Groningen, Leiden University Medical 
Center, Erasmus Medical Center Rotterdam, University 
Medical Center Utrecht, St Elisabeth Hospital Tilburg 
and Academic Medical Center Amsterdam). The RIVM 
reported genotyping results of samples referred by 
17 of 26 virology laboratories across the Netherlands 
that do not perform typing. A total of 1,917 EV-positive 
samples that had been genotyped were reported dur-
ing the study period. The EV-B species was the most 
frequently detected species in all five years taken 
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together, accounting for 70.3% (n = 1,347) of the 
viruses detected. The EV-A species comprised the 
second major species (24.4%, n = 467). The EV-C spe-
cies and EV-D species (all identified as type EV-D68) 
accounted for 1.4% (n = 25) and 4% (n = 77), respec-
tively, of the viruses detected. Oral PV vaccine (OPV) 
strains were detected in four patients; two cases in 
2010 with OPV2 and OPV3, respectively, and two cases 
in 2011 also with OPV2 and OPV3, respectively. The 
five most commonly reported types and their ranking 
varied each year and accounted in total for 49–63% of 
the infections identified (Table).
Figure 2
Distribution of epidemic enterovirus types, the Netherlands, 1996–2014 (classical surveillance; n = 938 and 2010–2014 
(VIRO-TypeNed; n = 619)
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Lineages are indicated in boxes in the graphs. Black bars indicate classical surveillance. Orange bars indicate VIRO-TypeNed data.
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Endemic circulation
Types that were characterised as endemic cyclic were 
E-25 (n = 136), E-30 (n = 123), CV-A9 (n = 113), CV-B3 
(n = 98), E-18 (n = 73), CV-B4 (n = 69), E-9 (n = 67) and 
E-7 (n = 62); they occurred with sharp peaks every two 
to four years (Figure 1). While there was no clear pat-
tern indicative of evolution, phylogenetic clustering 
(data not shown) suggested the circulation of distinct 
genetic lineages that were defined by genetic changes 
in different motifs of the VP1 gene. E-9, E-18, E-25, E-30 
and CV-B3 lineages were temporally defined (Figure 
1), indicating continuous temporal displacement of 
variants. CV-A9 and CV-B4 showed no sequence diver-
gence between the years (Figure 1). All E-7 strains were 
collected in 2011 and were genetically similar. For all 
types, we found that the genetic changes were primar-
ily silent. In addition to these silent changes, E-25, 
CV-B3 and E-9 variants showed amino acid substitu-
tions within the B/C loop, suggesting antigenic diver-
sification over time. E-25 strains encoded a valine (V, 
lineage b and d) or threonine (T, lineages a and e) at 
position 78 and an aspartic acid (D, lineage b and a) 
or asparagine (N, lineage d and e) at position 86 of 
the E-25 VP1 protein (amino acid numbering based on 
GenBank accession number HM03119). CV-B3 strains 
encoded a lysine (K, lineage a) or asparagine (N, line-
age b) at position 85 of the CV-B3-VP1 protein (num-
bering based on GenBank accession number JX312064) 
and E-9 carried an asparagine (N, lineage a) or aspartic 
acid (D, lineage b) at position 84 of the E-9 VP1 pro-
tein (numbering based on GenBank accession number 
AF524866) [44,51,52].
Epidemic circulation
Types that were characterised as epidemic were E-16 
(n = 212), CV-A6 (n = 126), CV-A16 (n = 89), EV-A71 
(n = 77, of which 69 were C2), EV-D68 (n = 77) and E-5 
(n = 38). E-16 was frequently reported in 2014 and was 
detected in 29% of the infections in the summer of 
2014, which was twice as much than any other type 
detected in previous years (Figure 2).
Of interest is that CV-A6, CV-A16 and EV-A71 has con-
tinuously been detected in an endemic cyclic pattern 
since 2010 (Figure 2). Sequence divergence between 
CV-A6 lineages and EV-A71 C2 sublineages were pri-
marily silent and were temporally defined (Figure 2), 
indicating the same continuous displacement of vari-
ants as seen for the endemic types. In contrast, CV-A16 
variants did not display any significant sequence varia-
tions defining temporal clustering (Figure 2).
The shift from epidemic to endemic cycle was observed 
also for EV-D68. An upsurge of EV-D68 has been 
observed in 2010, after very low frequency for 14 years, 
and again in 2014 (Figure 2). The EV-D68 strains from 
2010 and 2014 clustered as temporally defined sub-
lineages within the previously assigned lineages A/III 
and B/I (Figure 2). Sequence divergence between the 
two lineages showed amino acid substitutions within 
the B/C loop; the variants of the 2014 B/I lineage were 
found to encode D90, T92 and alanine (A)95 of the 
VP1 protein (amino acid numbering based on GenBank 
accession AB061487). The variants of the 2010 and 
2014 A/III lineages were found to encode N90, A92 
(2010, lineage a) or T92 (2014, lineage b), and glutamic 
acid (E)95 (Figure 2).
Patient characteristics
Using additional patient data submitted to VIRO-
TypeNed, we analysed factors such as age of infection, 
sex and clinical symptoms and their influence on the 
occurrence of endemic and epidemic patterns of the 
different types. The female:male sex ratio varied con-
siderably between the types and there was no differ-
ence between endemic and epidemic types. Infections 
were frequently or equally found among girls for the 
endemic types CV-A9 (ratio: 0.9) and CV-B4 (ratio: 0.9), 
and the epidemic types EV-D68 (ratio: 0.7) and CV-A6 
(ratio: 1). For most types, infections were frequently 
found among boys for the endemic types E-30 (ratio: 
1.1), CV-B3 (ratio: 1.2), E-25 (ratio: 1.3), E-5 (ratio: 1.9), 
E-18 (ratio: 1.7), E-9 (ratio: 1.5), E-18 (ratio: 1.7) and E-7 
(ratio: 2.4), and the epidemic types E-16 (ratio: 1.1), 
CV-A16 (ratio: 1.1) and EV-A71 (ratio: 1.5). 
Overall, infections were detected in cases of all ages 
(< 28 days to 85 years) with a majority of cases younger 
than five years (n = 1,067/1,249; 56%). Cases infected 
with the epidemic types E-5 and E-16 were predomi-
nantly younger than three months (n = 18/38; 47% and 
n = 159/212; 75%, respectively). In contrast to the EV-B 
types characterised as either endemic or epidemic, 
cases infected with EV-A types were predominantly 
one to two years of age (25–35%): CV-A6 (n = 38/126), 
CV-A16 (n = 24/89), EV-A71 (n = 19/77) and the EV-D 
type EV-D68 (n = 25/77). A number of viruses were also 
frequently found in adults (at parenting age, 25–45 
years) in 3–20% of the cases: E-30 (n=15/123), CV-A9 
(n=11/113), E-18 (n = 8/73), CV-A6 (n = 14/126), CV-A16 
(n = 5/89) and EV-A71 (n = 3/77). Adult infections with 
EV-D68 were also frequently found among cases aged 
45 to 65 years (n = 12; 16%). No adults with E-25, CV-B3 
and E-9 infections were identified. Adults infected with 
other EV-B comprised less than 1% of the infections. 
Clinical information was reported for only 5–30% of 
the cases. Nonetheless, it was found that all HFMD dis-
ease reports were attributed to EV-A infections (10/25, 
p = 0.003). Neurological symptoms were statistically 
more frequently reported among EV-B-infected cases 
(85/129) compared with only a few EV-A-infected cases 
(8/21) (p = 0.027).
Seasonal distribution
Because typing data were linked to date of isolation, 
VIRO-TypeNed enabled direct analysis of seasonal 
trends of new upsurges of the common types as well 
as trends between the types. A clear seasonal distribu-
tion was observed in the years 2010, 2013 and 2014, 
with 15–29% of the EV infections observed in July and 
August of those years. In some years, there were clear 
seasonal peaks in winter, contrary to the summer peaks 
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that are considered typical for enteroviruses. In 2011 
and 2012, most EV infections detected in those years 
were found in the late fall and winter 2011/12 (October 
to February; detection ranged from 16% in October 
2011 to 9% in February 2012). In contrast, not many 
summer infections were reported in those years (11% 
in July 2011 and 6% in August 2012). When an upsurge 
was detected after more than 10 years of low EV activ-
ity, the epidemic types CV-A6, CV-A16, EV-D68 and E-5 
were predominantly detected in the winter. For CV-A6, 
CV-A16 and EV-D68, the seasonality shifted towards 
summer and fall in the following years.
Discussion 
In this paper, we describe the systematic surveil-
lance of NPEVs for the Netherlands through the VIRO-
TypeNed system, which is based on molecular typing 
of pathogens.
By analysing virus sequence data in combination with 
epidemiological and patient data, we show for the first 
time in a standardised manner the circulation pat-
terns of NPEVs in the Netherlands enabling a better 
understanding of NPEV circulation, which is required 
to control and curtail outbreaks and upsurges. With 
the knowledge on the endemic cyclic patterns, a rise 
in the number of positive cases two to four years after 
the last upsurge warrants vigilance because it could 
indicate an imminent upsurge/outbreak [53]. Of inter-
est is the shift from an epidemic to an endemic pat-
tern for CV-A6, CV-A16, EV-A71 and EV-D68; this should 
be taken into account when monitoring rare types. For 
the EV-A viruses, the observed shift could be a surveil-
lance artefact due to the change in detection methods 
from culture to molecular, as molecular methods have 
increased sensitivity and capture viruses that are more 
difficult to culture, such as these EV-A viruses [31-
33,36]. Another explanation could be a change in path-
ogenicity. We found a low level of circulation of EV-D68 
(before 2010) and EV-C viruses, which is consistent 
with other studies (reviewed by [31]) and is suggested 
to be related to a low pathogenicity of these types [43]. 
Indeed, in 2010 and 2014, hospitals in Europe and the 
US reported increased detection of EV-D68 in respira-
tory samples from cases with severe respiratory dis-
ease [24-29,50,54-57]. 
The increase was related to genetic changes that could 
have driven a more severe pathogenicity rather than 
to changes in detection methods [50]. Unfortunately, 
clinical data were missing in the majority of cases of 
other viruses and more data are required to investigate 
whether pathogen drift could have additionally con-
tributed to the increased detection of other NPEVS in 
certain years.
The data further suggest that the epidemic/endemic 
cyclic patterns might be driven by immunity; this could 
be due to antigenic diversification, waning immunity 
or simply lack of immunity. The frequency of infec-
tions at an extremely young age and at parenting age 
[58-60] suggests lack of protection by maternal anti-
bodies [61]. Lack of immunity or waning immunity can 
be inversely related to the endemic cyclic patterns 
of the different types/strains; the types/strains that 
adults are exposed to are different from those circu-
lating during their childhood when they frequently 
came in contact with EVs. An adult’s immunity profile 
is thus directed against EV types not currently circu-
lating, which has led to a high proportion of suscepti-
ble adults. In the case of antigenic diversification, the 
immunity that was predominantly built up in previous 
years may be lacking (loss of neutralisation capacity) 
or not effective against currently circulating antigenic 
variants (altered neutralisation capacity) [62]; this 
also leads to a high proportion of susceptible adults 
[24,50,54]. For EV-D68, the high proportion of infection 
among adult cases aged 45 to 65 years, and the diver-
gence between the two lineages showing amino acid 
substitutions within the B/C loop, indeed suggest that 
antigenic diversification leading to altered neutralisa-
tion capacity plays a role in adult infections [50,54]. In 
contrast, E-30, CV-A9, E-18, CV-A6, CV-A16 and EV-A71, 
all frequently observed in adult infections, showed no 
antigenic diversification. However, we cannot rule out 
the occurrence of antigenic diversification among these 
types, as antigenic epitopes can also be found among 
other exposed VP1 loops and on other capsid proteins 
[44,51,52] not characterised by the Nix protocol.
Furthermore, no adults were identified among E-25, 
CV-B3 and E-9, strains proposed to have antigenic 
diversification. This would suggest that other factors 
act as a transmission bottleneck, such as differential 
receptor expression between adults and children. It 
has been suggested that viral characteristics such as 
receptor usage can account for the differential age of 
infection with several EV types and HPeV [19,63].
Another factor affecting the circulation patterns is 
seasonality. It has been suggested that infection fre-
quency is dependent on the number of contacts or 
transmissions, which can be influenced by the season 
or the weather. The frequency of contacts is highest 
during the winter months [64-66], which could spur 
widespread transmission after an initial introduc-
tion and lead to unexplained illness outbreaks dur-
ing winter season. The observed winter peak could be 
Table
The five most frequent non-polio enterovirus infections 
collected by VIRO-TypeNed, the Netherlands, 2010–2014 
(n = 1,917)
Ranking 2010 2011 2012 2013 2014
1 CV-A9 E-25 E-18 CV-B3 E-16
2 EV-A71 E-7 CV-A6 CV-A9 E-25
3 E-30 CV-B3 E-9 E-30 CV-A6
4 EV-D68 CV-B4 CV-A16 EV-A71 CV-A16
5 CV-A16 E-9 E-5 CV-A6 EV-D68
The ranking is based on the number of cases recorded.
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related to the introduction of fast molecular methods 
that allowed rapid screening of samples throughout 
the years, revealing a more diverse seasonal pattern. 
EV should therefore also be considered in the differ-
ential diagnosis during winter seasons, contrary to the 
dogma describing EV infections as seasonal summer 
infections.
To investigate and understand the role of these factors 
(antigenic diversification, lack of or waning immunity, 
and seasonality) on the circulation pattern, full-length 
genetic and phenotypic analysis in combination with 
sero-population studies need to be conducted over an 
extended period. VIRO-TypeNed provides a platform to 
analyse these data in relation to one another.
Knowledge about the endemic/epidemic patterns can 
be used to investigate the possibility of type-specific 
vaccines [67]. Meanwhile, the data can be used to pre-
screen intravenous immunoglobulin (IVIG) products, 
where the knowledge of which types are currently cir-
culating can enable a more effective use of IVIGs.
Furthermore, with the current developments in the 
antiviral field, EV infections may soon be classified as 
treatable rather than life-threatening [13]. The drugs 
currently in development show type-specific efficacy 
[68,69] and use requires the knowledge of which types 
are currently circulating or may cause an outbreak.
While VIRO-TypeNed provides data on NPEVs, the sys-
tem also allows reporting the detection of PV. PV cir-
culation might occur through inadvertent introduction 
of OPV, vaccine-derived PV (VDPV) or even wild-type 
PV, or via faecal excretions from migrants or travellers 
returning from endemic or OPV-using countries. Any 
type of PV isolation in the Netherlands leads to a pub-
lic health alert because there is a large unvaccinated 
group (3% of the population) refusing vaccination for 
religious reasons that live in a closely isolated commu-
nity (the Bible Belt). The 5’UTR PCR is able to detect 
all EVs including PV. Over the period studied, four OPV 
strains were reported. They had been detected by direct 
genotyping from clinical samples and had already 
been notified to the RIVM, and preventive actions for 
further spread had been taken. Given the very low cir-
culation rate of PV in the Netherlands in non-epidemic 
years, EV-positive samples from which unique NPEV 
sequences are generated are considered PV-negative. 
However, as positive untyped samples can contain PV, 
laboratories are encouraged to send these samples, in 
particular those with suspicion of PV infection, to the 
RIVM for cultivation on L20B cells. As such, the surveil-
lance capacity to exclude PV circulation in a molecular 
era is maintained.
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